NOVAVAX INC (NVAX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NVAX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NVAX | [] | ["Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| FOLD | Chair of the Board of Directors | 65 | ["Retired from Merck & Company after 26 years", "President of Global Vaccines and Infectious Disease", "President, U.S. Hospital and Specialty Products", "Chief Executive Officer and President of The International AIDS Vaccine Initiative", "Executive leadership roles in global and U.S. marketing, sales, and managed care", "Chair of the Board of HCU Network America", "Trustee of University at Buffalo Foundation", "Holds a B.S. in Pharmacy and a M.B.A. in Marketing", "Honorary doctorate in sciences from the State University of New York at Buffalo"] | ["Compensation and Leadership Development"] | 2025 |
| VRTX | Chair | [] | ["Corporate Governance and Nominating Committee"] | 2023 | |
| APD | Retired President, Merck & Co. Inc. Global Vaccine and Infectious Disease Division and Retired President and Chief Executive Officer of International AIDS Vaccine Initiative; Director | 60 | ["Extensive experience in government relations and public policy", "International marketing", "Mergers and acquisitions", "Talent management", "Expertise in productivity", "Deep understanding of the healthcare business"] | ["Corporate Governance", "Nominating", "Management Development", "Compensation"] | 2019 |